These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 26847591)

  • 1. Beneficial effects of JAK inhibitor therapy in Systemic Mastocytosis.
    Dowse R; Ibrahim M; McLornan DP; Moonim MT; Harrison CN; Radia DH
    Br J Haematol; 2017 Jan; 176(2):324-327. PubMed ID: 26847591
    [No Abstract]   [Full Text] [Related]  

  • 2. Jak-inhibitors and UV-B: Potential combined therapy for vitiligo.
    Urso B
    Dermatol Ther; 2017 Sep; 30(5):. PubMed ID: 28833974
    [No Abstract]   [Full Text] [Related]  

  • 3. Emerging therapies for atopic dermatitis: JAK inhibitors.
    Cotter DG; Schairer D; Eichenfield L
    J Am Acad Dermatol; 2018 Mar; 78(3 Suppl 1):S53-S62. PubMed ID: 29248518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. JAK inhibitors: Novel developments in management of ulcerative colitis.
    Fiorino G; D'Amico F; Italia A; Gilardi D; Furfaro F; Danese S
    Best Pract Res Clin Gastroenterol; 2018; 32-33():89-93. PubMed ID: 30060943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Aggressive systemic mastocytosis: report of a case].
    Wang M; Yang QP; Wang XQ; Xu X; Liu WP
    Zhonghua Bing Li Xue Za Zhi; 2010 Nov; 39(11):775-7. PubMed ID: 21215173
    [No Abstract]   [Full Text] [Related]  

  • 6. Identification of 2-Imidazopyridine and 2-Aminopyridone Purinones as Potent Pan-Janus Kinase (JAK) Inhibitors for the Inhaled Treatment of Respiratory Diseases.
    Bach J; Eastwood P; González J; Gómez E; Alonso JA; Fonquerna S; Lozoya E; Orellana A; Maldonado M; Calaf E; Albertí J; Pérez J; Andrés A; Prats N; Carreño C; Calama E; De Alba J; Calbet M; Miralpeix M; Ramis I
    J Med Chem; 2019 Oct; 62(20):9045-9060. PubMed ID: 31609613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of systemic mastocytosis with denileukin diftitox.
    Quintás-Cardama A; Kantarjian H; Verstovsek S
    Am J Hematol; 2007 Dec; 82(12):1124. PubMed ID: 17665501
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment of CD30-positive systemic mastocytosis with brentuximab vedotin.
    Borate U; Mehta A; Reddy V; Tsai M; Josephson N; Schnadig I
    Leuk Res; 2016 May; 44():25-31. PubMed ID: 26994848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thalidomide in advanced mastocytosis.
    Damaj G; Bernit E; Ghez D; Claisse JF; Schleinitz N; Harlé JR; Canioni D; Hermine O
    Br J Haematol; 2008 Apr; 141(2):249-53. PubMed ID: 18307561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ["Smoldering systemic mastocytosis. "Successful therapy with cladribine].
    Schleyer V; Meyer S; Landthaler M; Szeimies RM
    Hautarzt; 2004 Jul; 55(7):658-62. PubMed ID: 15241520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone involvement and osteoporosis in mastocytosis.
    Rossini M; Zanotti R; Viapiana O; Tripi G; Orsolini G; Idolazzi L; Bonadonna P; Schena D; Escribano L; Adami S; Gatti D
    Immunol Allergy Clin North Am; 2014 May; 34(2):383-96. PubMed ID: 24745681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Systemic mastocytosis].
    Sökler M; Kanz L
    Dtsch Med Wochenschr; 2005 Oct; Suppl 1():96. PubMed ID: 16379260
    [No Abstract]   [Full Text] [Related]  

  • 13. Imatinib mesylate for aggressive systemic mastocytosis with long bone osteolysis.
    Jung AG; Horny HP; Sotlar K; Overbeck T; Schön MP; Lippert U
    J Am Acad Dermatol; 2011 Jul; 65(1):224-6. PubMed ID: 21679828
    [No Abstract]   [Full Text] [Related]  

  • 14. Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis.
    Carter MC; Robyn JA; Bressler PB; Walker JC; Shapiro GG; Metcalfe DD
    J Allergy Clin Immunol; 2007 Jun; 119(6):1550-1. PubMed ID: 17481708
    [No Abstract]   [Full Text] [Related]  

  • 15. A new humanized in vivo model of KIT D816V+ advanced systemic mastocytosis monitored using a secreted luciferase.
    Bibi S; Zhang Y; Hugonin C; Mangean MD; He L; Wedeh G; Launay JM; Van Rijn S; Würdinger T; Louache F; Arock M
    Oncotarget; 2016 Dec; 7(50):82985-83000. PubMed ID: 27783996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Systemic mastocytosis].
    Fain O; Stirnemann J; Lortholary O
    Rev Prat; 2005 Oct; 55(15):1629-36. PubMed ID: 16334197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients.
    Escribano L; Alvarez-Twose I; Sánchez-Muñoz L; Garcia-Montero A; Núñez R; Almeida J; Jara-Acevedo M; Teodósio C; García-Cosío M; Bellas C; Orfao A
    J Allergy Clin Immunol; 2009 Sep; 124(3):514-21. PubMed ID: 19541349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complete response after imatinib mesylate therapy in a patient with well-differentiated systemic mastocytosis.
    Alvarez-Twose I; González P; Morgado JM; Jara-Acevedo M; Sánchez-Muñoz L; Matito A; Mollejo M; Orfao A; Escribano L
    J Clin Oncol; 2012 Apr; 30(12):e126-9. PubMed ID: 22370312
    [No Abstract]   [Full Text] [Related]  

  • 19. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.
    Schwartz DM; Kanno Y; Villarino A; Ward M; Gadina M; O'Shea JJ
    Nat Rev Drug Discov; 2017 Dec; 16(12):843-862. PubMed ID: 29104284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imatinib mesylate responsiveness in aggressive systemic mastocytosis: novel association with a platelet derived growth factor receptor beta mutation.
    Dalal BI; Horsman DE; Bruyèrè H; Forrest DL
    Am J Hematol; 2007 Jan; 82(1):77-9. PubMed ID: 17133421
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.